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INTRODUCTION
Spinal muscular atrophy (SMA) is one of the most common
autosomal recessive disorders characterized by progressive
muscle weakness caused by degeneration of the spinal ante-
rior horn cells. SMA has a prevalence of 1/6,000 to 1/10,000
births and a carrier frequency of 1/40 to 1/50 (1-3). Accord-
ing to age of onset and severity of symptoms, patients with
SMA are subdivided into three clinical types (4). Type I (Werd-
nig-Hoffmann disease; OMIM 253300) is the most severe
form with the onset at birth to the first few month and death
by 2 yr of life. Type II (OMIM 253550), intermediate form,
is characterized by the onset before 18 months of age and
survival beyond 4 yr-old age. Type III (Kugelberg-Welander
disease; OMIM 253400) is the mildest form with the onset
after the age of 2 yr and survival into adulthood.
All types of SMA are associated with homozygous deletion
in the survival motor neuron 1 gene (SMN1; OMIM 600354)
(5). SMN1 and its homologous gene, SMN2 (OMIM 601627),
are located on 5q13. The two SMN genes are different at only
five nucleotide exchanges within their 3′ ends (5, 6). In con-
trast to SMN1, the expression of SMN2 protein is truncated
from skipping of exon 7 by a single nucleotide exchange
(840C→T) (7, 8). Approximately 94% of SMA patients lack
both copies of SMN1 exon 7 (9), which can be detected by
the commonly used molecular analyses (2, 10).
As the carrier frequency in population is high, the carrier
test for SMA is important issue in genetic counseling. Until
now, several quantitative PCR methods for SMN1 analysis
have been developed for carrier detection (11-14). However,
these methods were intricate and easily submitted to errors.
Recently reported quantitative real-time PCR assays (15, 16)
allow the specific amplification of only SMN1 gene, and be-
come powerful tools to avoid these problems. However, these
tests include still several limitations in relation to the speci-
ficity, and cost-effectiveness.
In consideration of these defects, we developed a reliable
quantitative real-time PCR method using SMN1 gene spe-
cific primers and SYBR Green I dye for the carrier detection
of SMA. The comparative Ct (threshold cycle) method was
used to quantify the copy numbers of SMN1 gene. This test
allowed us to analyze a large number of samples efficiently.
Here, we report the results of quantitative analysis of SMN1
gene in SMA patients and parents, and the estimated carrier
frequency in Korean population. 
MATERIALS AND METHODS
Subjects
Quantitative analysis of SMN1 gene was done in 13 patients
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Quantitative Analysis of SMN1 Gene and Estimation of SMN1 Deletion
Carrier Frequency in Korean Population based on Real-Time PCR
Spinal muscular atrophy (SMA) is an autosomal recessive disorder, caused by
homozygous absence of the survival motor neuron gene (SMN1) in approximately
94% of patients. Since most carriers have only one SMN1 gene copy, several
SMN1 quantitative analyses have been used for the SMA carrier detection. We
developed a reliable quantitative real-time PCR with SYBR Green I dye and stud-
ied 13 patients with SMA and their 24 parents, as well as 326 healthy normal indi-
viduals. The copy number of the SMN1 gene was determined by the comparative
threshold cycle (Ct) method and albumin was used as a reference gene. The
homozygous SMN1 deletion ratio of patients was 0.00 and the hemizygous SMN1
deletion ratio of parents ranged from 0.39 to 0.59. The  Ct ratios of 7 persons
among 326 normal individuals were within the carrier range, 0.41-0.57. According
to these data, we estimated the carrier and disease prevalence of SMA at 1/47
and 1/8,496 in Korean population, respectively. These data indicated that there
would be no much difference in disease prevalence of SMA compared with west-
ern countries. Since the prevalence of SMA is higher than other autosomal reces-
sive disorders, the carrier detection method using real-time PCR could be a useful
tool for genetic counseling.
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with SMA and their 24 parents. Clinical diagnosis was ful-
filled on all patients and homozygous absence of SMN1 exon
7 was confirmed with polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP) (2, 10).
To estimate the carrier frequency in Korean population,
we selected 326 unrelated healthy individuals aged 19-81
yr who participated in a comprehensive health screening in
Ansan Health Center (17). Informed consents for DNA analy-
sis were obtained from the patients and normal individuals. 
DNA extraction
Genomic DNA was extracted from peripheral blood sam-
ples by the QIAamp DNA blood kit (Qiagen, Hilden, Ger-
many) and was measured by an Ultrospec
�2100 (Amersham
Pharmacia Biotech, Piscataway, NJ, U.S.A.). Samples that
had purity in the range of 1.5-1.8 (260 nm/280 nm ratio)
were used for highly efficient amplification. DNAs were
diluted to a final concentration of 2.5 ng/ L.
Quantitative real-time PCR of SMN1
The quantitative real-time PCR assay was based on pri-
mers that specifically amplify SMN1 gene. To distinguish
SMN1 from SMN2 (GenBank AH006635) in the amplica-
tion reactions, 3 ends of the primers were designed to end
on the SMN1 specific sequence in exon 7 at position 6 and
intron 7 at position +2: forward primer is 5 -CCTTTTAT-
TTTCCTTACAGGGTTTC-3 ; reverse primer is 5 -GATT-
GTTTTACATTAACCTTTCAACTTTT-3 . Specificity of
the SMN1 primers was confirmed by multiplex PCR with
COL1A1 gene (forward primer, 5 -GGGGGAACAAGGC-
TGTCT-3 ; reverse primer, 5 -TCCTGGGGTTCAGACCA-
A-3 ) in patient samples and a normal individual’s. As a ref-
erence gene, we used exon 12 of human serum albumin: for-
ward primer is 5 -AGCTATCCGTGGTCCTGAAC-3; re-
verse primer is 5 -TTCTCAGAAAGTGTGCATATATCT-
G-3 . Using the ABI PRISM
�7700 Sequence Detection Sys-
tem (PE Applied Biosystems, Foster City, CA, U.S.A.), the
PCR was performed in a total volume of 20  L in each well,
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Fig. 1. Real-time amplification plots of triplicate SMN1 and albu-
min of: (A) healthy normal control ( Ct ratio 1.04, SD SMN1
0.09, SD albumin 0.01); (B) carrier with one SMN1 copy ( Ct
ratio 0.5, SD SMN1 0.01, SD albumin 0.14); (C) patients with
SMA of homozygous absence of SMN1 ( Ct ratio 0.00, SD
albumin 0.14, no amplification of SMN1).
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containing 10  L of SYBR Green
� PCR Master Mix (PE
Applied Biosystems), 20 ng of genomic DNA (8  L), and
0.1  M and 0.5  M of SMN1 and albumin primers, which
was determined after the analysis of the optimal concentra-
tions of each primer. Each sample was run in triplicates in
separate tubes to permit quantification of the SMN1 gene nor-
malized to albumin. The PCR condition consisted of initial
denaturation step of 95℃for 10 min, followed by 40 cycles
of 95℃for 15 sec and 60℃for 1 min. 
Data analysis
All data were calculated by the comparative Ct method,
to detect the relative gene copy numbers (18). By using a cali-
brator sample of a normal control DNA, the gene copy num-
bers of unknown samples were estimated. Patients, carrier,
and unrelated normal samples were analyzed together with
the calibrator sample on every assay plate.  Ct represents the
mean Ct value of each sample and was calculated for SMN1
and albumin. The gene copy numbers of the samples were
determined by the following formula:  Ct=[ Ct albumin
(calibrator sample)- Ct SMN1 (calibrator sample)]-[ Ct
albumin (unknown sample)- Ct SMN1 (unknown sample)].
The relative gene copy numbers were calculated by the expres-
sion 2-C t . Using this method, a  Ct ratio, [2-C t ], was
expected to be about 1 in normal controls, about 0.5 in car-
riers and 0 in patients with SMA.
RESULTS
The Ct values of SMN1 and albumin triplicates showed
almost identical at the amplification plots of a normal con-
trol (Fig. 1A). The standard deviations of triplicate Ct val-
ues for all samples were very low (mean, 0.10; range, 0.00-
0.32). In parents of SMA patients, carrying only one SMN1
gene copy, the Ct values of SMN1 increased about 1.32 com-
pared with albumin (Fig. 1B). In the SMA patients, the albu-
min gene was amplified as in normal controls, but the SMN1
gene was not amplified as expected (Fig. 1C). Their  Ct
ratios were 0.00 showing homozygous absence of SMN1 gene.
In accordance with this result, there were no visible products
of the SMN1 genes in SMA patients by multiplex PCR with
COL1A1 gene (Fig. 2). The range of measured  Ct ratios
in 24 parents was between 0.39 and 0.59 (Table 1). To esti-
mate the frequency of carrier in general population, we test-
ed 326 healthy individuals. Among them,  Ct ratios of
7 persons were within the carrier range, 0.41-0.57, indicat-
ing that the carrier prevalence was about 1/47 in Korean pop-
ulation (Table 2). The others were detected between 0.84 and
2.19. This result was classified into three groups according
to the expected copy numbers of SMN1 (Table 2). 
DISCUSSION
SMA carrier test based on direct quantitative analysis of
SMN1 gene is one of the most important issues, since homozy-
gous deletion of SMN1 exon 7 is a common variant. However,
the reports of SMA carrier frequency have been concentrated
in western countries (3, 11). Therefore, we tried to calculate
the SMA carrier frequency in Korea and developed the reli-
able quantitative test of SMN1 based on real-time PCR with
the SYBR Green I dye using the comparative Ct method. We
used primers ending on to the nucleotide exchanges between
the SMN1 and SMN2 genes in exon 7 to distinguish the
SMN1 and SMN2 genes. The specificity and sensitivity of
the test are 100%, although the presence of two SMN1 copies
per chromosome or intragenic point mutations in some of
the SMA chromosomes (approximately 5%) slightly decreases
the sensitivity of the test.
We determined the range of carrier gene dosage in 24 par-
ents (0.39-0.59) of SMA patients, in which homozygous dele-
tion of SMN1 gene were identified previously by PCR-RFLP
(Table 1), and then screened 326 healthy normal individu-
als. As shown in Tables 1 and 2, there is no overlap between
the range of  Ct ratio measured SMN1 copy numbers in
SD, standard deviation; CV, coefficient of variation.
Subjects
Ct ratio of SMN1 gene
Mean Range SD CV (%)
Patient (n=13) 0.00 0.00-0.00 --
Parent (n=24) 0.53 0.39-0.59 0.12 6.1
Normal (n=326) 1.12 0.41-2.19 0.25 18.5
Table 1. Real-time quantitative analysis of SMN1 gene copy
number using a comparative Ct method ( Ct ratio) in patients,
carriers, and normal individuals
Expected copy
number of
Ct ratio
range
No. in general
population
Frequency (%)
1 0.41-0.57 7 2.2
2 0.84-1.25 254 77.9
3 1.41-1.64 62 19.0
4 1.90-2.19 3 0.9
Total 326 100.0
Table 2. SMN1 gene copy numbers in Korean population
Fig. 2. Identification of specificity of SMN1 primers in three SMA
families and a normal individual by multiplex PCR with COL1A1.
P, patient; F, father; M, Mother.
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carriers and normal individuals. The prevalence of carrier was
1/47 in Korean population (95% confidence interval: 1/175-
1/27), within the similar ranges reported in western coun-
tries (1, 3, 11). In 65 individuals, the SMN1 copy numbers
were three or four copies like as in other countries (11-13).
Since SMA is a fatal disease, coefficient of selection of SMN1
deleted homozygotes is almost one. Therefore, extrapolation
of Hardy-Weinberg equation to calculate the prevalence of
SMN1 deleted homozygotes in a population seems to be unrea-
sonable. Nevertheless, if ignoring this potential bias, the dis-
ease prevalence of SMN1 deleted homozygotes calculated by
Hardy-Weinberg equation was 1/8,496 in Koreans. The esti-
mated prevalence was also not much different from those of
other European countries. Since there was no available infor-
mation of SMA prevalence in East Asian countries includ-
ing Korea, estimated prevalence presented in this study would
be valuable for pursuing SMA pathogenesis and genetic coun-
seling.
The SMN2, highly homologous gene of SMN1, is a well-
established disease-modifying gene for SMA and has been
shown to decrease the severity of type I-III SMA in gene dosage
analyses (11, 15, 19). The copy number of SMN2 also corre-
lates with longer survival of individuals affected with type I
SMA (15). Thus, the quantitative analysis of SMN2 gene
enables it possible to predict that an infant with homozygous
deletion of SMN1 develop type I, II or III SMA. Although
we did not carry out the assay of SMN2 gene in the present
study, our real-time quantitative PCR analysis could produce
sufficient results.
In conclusion, we detected SMN1 deletion carriers in a
general population and calculated the prevalence as the advan-
tages of real-time PCR with SYBR Green I. With relatively
high frequency of SMA compared with other autosomal reces-
sive disorders, the carrier detection method using real-time
PCR could be a useful tool for genetic counseling. 
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